Seeking Alpha

Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study...

Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study of two Phase III trials that compared its Lymphoseek radiopharmaceutical injection with a commonly used agent. Lymphoseek "demonstrated reliable detection of lymph nodes" in patients with breast cancer and melanoma over a period of 15 minutes up to 30 hours, a time range that may be encountered in a clinic. (PR)
Comments (1)
  • joelkatz
    , contributor
    Comments (448) | Send Message
     
    NAVB has hit its bottom at $2.38, guys and gals, time to join and get in.
    12 Jun 2013, 11:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|